5:53 PM
 | 
Aug 03, 2015
 |  BC Extra  |  Company News

Teva buying majority stake in Immuneering

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will acquire a 51% stake in computational genomic analysis company Immuneering Corp. (Cambridge, Mass.). Teva spokesperson Denise Bradley said Teva will pay Immunoneering $45 million in three tranches, and will receive exclusive right of first refusal for Immuneering...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >